Drug Trial Radar · NCT01276223
Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients
Last checked: Nov 20, 2026Latest source record: Mar 11, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
722
Actual
Start
Feb 2011
Primary completion
Jan 2012
Study completion Jan 2012
Sponsor
- Lead sponsor
- Alcon ResearchIndustry
- Sponsor type
- Industry
- First posted
- Jan 13, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study was to determine if difluprednate ophthalmic emulsion is effective in reducing the ocular symptoms of dry eye disease, as measured by a global Visual Analog Scale (VAS) discomfort score.
Conditions
- Dry Eye Disease
Interventions
Difluprednate 0.05% ophthalmic emulsionDrug
Topical ocular steroid
Difluprednate vehicleOther
Inactive ingredients used as Run-In and placebo comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline (Week 0) in Visual Analog Scale (VAS) Global Ocular Discomfort Score Over 4 WeeksTime frame: Baseline, up to 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Contact Alcon Call Center at 1-888-451-3937 for Trial Locations
Fort Worth, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.